Kenneth G. Saag, MD, MSc, is a nationally recognized expert & researcher in the epidemiology of gout, osteoporosis & rheumatoid arthritis. Dr. Saag brings a penchant for problem solving & a strong belief in the power of collaboration to his newest role in the College as the 85th ACR president.
With more than 100 members, including rheumatologists, physician assistants and nurse practitioners, the NCRA is a dynamic, member-owned organization.
Additional training may be needed on the appearance of the maturing sacroiliac (SI) joint on MRI. In a recent study, researchers found local radiologists may mistake normal physiologic changes of a maturing SI joint as sacroiliitis in pediatric patients.
Through sessions and Community Hubs, attendees of ACR Convergence 2021 have multiple opportunities to connect with other rheumatology professionals. Here are some helpful tips from panelists.
In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…